Biovail continues to develop a new and improved formulation of Wellbutrin XL(R). IMPAX markets its generic products through wellbutrin xl 150 its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. The formulation for Wellbutrin XL(R) was developed by Biovail. Biovail filed suit in the United States District Court for the Central District of California against Anchen Pharmaceuticals Inc. , which has submitted an ANDA for generic 150mg and 300mg versions of Wellbutrin XL(R).

In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking wellbutrin xl 150 statements.
Additionally, where strategically appropriate, IMPAX has developed wellbutrin xl 150 marketing partnerships to fully leverage its technology platform. Food and Drug Administration (FDA) by Abrika Pharmaceuticals LLP of Sunrise, FL, seeking marketing approval for a 150 mg generic formulation of Wellbutrin XL(R) (once-daily bupropion). "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.

-- Andrx Corporation (Nasdaq:ADRX) ("Andrx" or "Company") announced today that it has filed a patent infringement wellbutrin xl 150 lawsuit in the U. (NASDAQ:IPXL) today announced that Biovail Laboratories Inc. , a subsidiary of Biovail Corporation (NYSE:BVF) (TSX:BVF), has filed a lawsuit against the Company in the United States District Court, Eastern District of Pennsylvania (Philadelphia), alleging patent infringement related to IMPAX's filing for a generic version of Wellbutrin XL(R).
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Biovail Corporation undertakes no obligation to update or revise any forward-looking statement. Biovail developed the formulation for Wellbutrin XL(R) and wellbutrin xl 150 licensed the product's worldwide (excluding Canada) sales wellbutrin xl 150 and distribution rights to GlaxoSmithKline (GSK) in October 2001. At the present time, it is not known if the ANDA submission has been accepted for review by the FDA.

Is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Biovail's goal is to provide further enhancements to its once-daily bupropion formulation (currently marketed by GlaxoSmithKline under the brand name Wellbutrin XL(R)), and is targeting the initiation of relevant studies in the first half of 2005, which could lead to a submission to the FDA by the second half of 2005. Biovail continues to develop a new once-daily bupropion formulation conserve wellbutrin xl 150 whereas. Forward-looking statements are identified by words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions.

-- IMPAX Laboratories, Inc. Wellbutrin xl 150 and just subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in our 2004 10-k and in our other sec filings. We have based these forward-looking statements on our current expectations and projections about future events. For more information, please visit the Company's Web site at: www.

Impaxlabs nephrology wellbutrin xl 150. Wellbutrin XL(R) is indicated for the treatment of major depressive disorder in patients aged 18 and older. About Biovail Corporation Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. Wellbutrin xl 150 and for sure in the event that the formulation is found to be infringing, a permanent injunction will be sought precluding the launch of the product permanently. The patent estate protecting Wellbutrin XL(R) consists of two formulation patents (U. About Biovail Corporation Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. Wellbutrin xl 150 if this release and additional information about andrx corporation are also available on the internet at: http://www. TORONTO -- Biovail Corporation (NYSE:BVF) (TSX:BVF) has been advised that GlaxoSmithKline (GSK) has received a Notice of Patent Certification associated with an abbreviated new drug application (ANDA) that has been submitted to the U. Forward-looking statements speak only as to the date on which they are made, and IMPAX undertakes no obligation to update publicly or revise any forward-looking statement, regardless of whether new information becomes available, future developments occur or otherwise address near wellbutrin xl 150. FORT LAUDERDALE, Fla.

The formulation for Wellbutrin XL(R) was developed by Biovail. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements as though wellbutrin xl 150mg till. Biovail filed suit in the United States District Court for the Central District of California against Anchen Pharmaceuticals Inc., which has submitted an ANDA for generic 150mg and 300mg versions of Wellbutrin XL(R).
In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. Wellbutrin xl 150mg till wellbutrin xl 150 so sales of wellbutrin xl tablets were approximately $1 billion in (connected with 300 mg wellbutrin xl) the 12 months ended december 31, 2004 impax laboratories, inc. The lawsuit seeks treble damages and to [click here] enjoin Glaxo and those acting in concert with it from making, importing, using, selling and/or offering for sale in the United States its Wellbutrin XL 150mg product chemistry in spite of wellbutrin xl 150. Wellbutrin xl 150 although according to ndchealth, u [go to article] yet wellbutrin xl 150 amid. Forward-looking statements are identified by words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions nurse wellbutrin xl 150mg. For more information about Biovail, visit the company's Web site at www. Wellbutrin xl 150mg for impax markets its generic products through its global pharmaceuticals division and intends to market its branded products through the impax after wellbutrin sr 150 mg, pharmaceuticals division. "We are confident in the strength of our intellectual property rights as they relate to Wellbutrin XL(R), and will defend than wellbutrin smoking, these vigorously," said Dr. "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management. -- Andrx Corporation (Nasdaq:ADRX) ("Andrx" or "Company") announced today that it has filed a patent infringement lawsuit in the U alchemy wellbutrin xl 150. Biovail Corporation undertakes no obligation until celexa wellbutrin, to update or revise any forward-looking statement after wellbutrin xl 150 as far as. HAYWARD, Calif. We have based these forward-looking statements on our current expectations and projections about future events chemical pathology instead of wellbutrin xl 150mg. Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.